307 related articles for article (PubMed ID: 31674320)
1. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.
Li N; Huang HY; Wu DW; Yang ZM; Wang J; Wang JS; Wang SH; Fang H; Yu Y; Bai Y; Yan Z; Cao Y; Jiang M; Liu YF; Li KY; Xu BH; Sun Y; He J
Lancet Oncol; 2019 Nov; 20(11):e619-e626. PubMed ID: 31674320
[TBL] [Abstract][Full Text] [Related]
2. Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010-2019.
Liu X; Wu S; Sun J; Ni S; Lu L; Hu W; Wei H; Zou Y; Li T; Li J; Mijiti B; Fang P; Zhao L; Zhou H; Xing X; Niu H; Cao Y
Pharmacol Res Perspect; 2021 Apr; 9(2):e00729. PubMed ID: 33660404
[TBL] [Abstract][Full Text] [Related]
3. Trends in Molecular Testing of Lung Cancer in Mainland People's Republic of China Over the Decade 2010 to 2019.
Li W; Lyu Y; Wang S; Zhou X; Ma J; Xu C; Fang L; Ying J;
JTO Clin Res Rep; 2021 Apr; 2(4):100163. PubMed ID: 34590013
[TBL] [Abstract][Full Text] [Related]
4. Pediatric Clinical Trials in Mainland China Over the Past Decade (From 2009 to 2020).
Wu WW; Ji X; Wang H; Chen F; Ding Q; Zhang GD; Li M; Wang SS; Ni MM; Liu QQ; Xu J; Wang Q
Front Med (Lausanne); 2021; 8():745676. PubMed ID: 34671625
[TBL] [Abstract][Full Text] [Related]
5. Recent landscape and trends for industry-sponsored pediatric clinical trials in China from 2013 to 2022.
Liu C; Liu Y; Ou L; Qi Y; Zhang J
Pediatr Investig; 2024 Mar; 8(1):12-20. PubMed ID: 38516137
[TBL] [Abstract][Full Text] [Related]
6. Current clinical trials on breast cancer in China: A systematic literature review.
Fan Y; Xu B
Cancer; 2020 Aug; 126 Suppl 16():3811-3818. PubMed ID: 32710659
[TBL] [Abstract][Full Text] [Related]
7. The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): A systematic review.
Chen H; Zhou Y; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Mar; 8():100097. PubMed ID: 34327425
[TBL] [Abstract][Full Text] [Related]
8. [Progress on clinical trials of cancer drugs in China, 2020].
Wu DW; Huang HY; Tang Y; Wang HX; Wang J; Wang SH; Fang H; Yang XY; Li J; Wang X; Liu LJ; Yan Y; Wang Q; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):218-223. PubMed ID: 33601488
[No Abstract] [Full Text] [Related]
9. [Progress on clinical trials of cancer drugs in China, 2019].
Huang HY; Wu DW; Wang HX; Wang J; Fan Q; Wang SH; Bai Y; Yu Y; Fang Y; Sun C; Fang H; Bai H; Wang X; Liu ZY; Jiang M; Liu Z; Wang XH; Li HY; Li N; Cao C; Xu BH; Sun Y; He J
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):127-132. PubMed ID: 32135647
[No Abstract] [Full Text] [Related]
10. Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution.
Huang H; Tang Y; Wu D; Meng X; Wang S; Wang J; Yu Y; Fang Y; Fang H; Zhu Q; Li N; Xu B; Sun Y; He J
BMC Geriatr; 2023 Mar; 23(1):199. PubMed ID: 36997858
[TBL] [Abstract][Full Text] [Related]
11. Trend of drug clinical trials in mainland China from 2009 to 2020.
Cao Y; Liao L; Liu X; Zheng Q; Xu Z; Niu H
Curr Med Res Opin; 2022 Sep; 38(9):1499-1507. PubMed ID: 35855662
[TBL] [Abstract][Full Text] [Related]
12. Current status and trend of clinical development of orphan drugs in China.
Xiang Z; Jiang W; Yan B; Jiang J; Zheng H
Orphanet J Rare Dis; 2022 Jul; 17(1):294. PubMed ID: 35897012
[TBL] [Abstract][Full Text] [Related]
13. Evolving paradigms for new agent development in pediatric oncology.
Flynn A; Fox E
Curr Opin Pediatr; 2018 Feb; 30(1):10-16. PubMed ID: 29176356
[TBL] [Abstract][Full Text] [Related]
14. The changing landscape of anti-lung cancer drug clinical trials in mainland China from 2005 to 2020.
Zhong Q; Tao Y; Chen H; Zhou Y; Huang L; Han X; Shi Y
Lancet Reg Health West Pac; 2021 Jun; 11():100151. PubMed ID: 34327360
[TBL] [Abstract][Full Text] [Related]
15. Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021.
Bo C; Wang T; Hou C; Han J; Chen L; Zhang H; Wang L; Li H
CNS Neurosci Ther; 2022 Aug; 28(8):1229-1239. PubMed ID: 35642775
[TBL] [Abstract][Full Text] [Related]
16. New approaches to therapeutic drug development for childhood cancers.
Campbell K; Ma C; DuBois SG
Curr Opin Pediatr; 2020 Feb; 32(1):35-40. PubMed ID: 31790026
[TBL] [Abstract][Full Text] [Related]
17. Challenges and Opportunities With Oncology Drug Development in China.
Bajaj G; Gupta M; Wang HH; Barrett JS; Tan M; Rupalla K; Bertz R; Sheng J
Clin Pharmacol Ther; 2019 Feb; 105(2):363-375. PubMed ID: 29328503
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials and drug approvals continue to accelerate in China.
Wang M
Lancet Oncol; 2017 Jul; 18(7):855. PubMed ID: 28552212
[No Abstract] [Full Text] [Related]
19. Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020.
Chen K; Jiang K; Tang L; Chen X; Hu J; Sun F
Front Oncol; 2021; 11():647110. PubMed ID: 34084744
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
